New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19—A Large Postmortem and Clinical Analysis

Critically ill COVID-19 patients are at high risk for venous thromboembolism (VTE), namely deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and death. The optimal anticoagulation strategy in critically ill patients with COVID-19 remains unknown. This study investigated the ante mortem incidence as well as postmortem prevalence of VTE, the factors predictive of VTE, and the impact of changed anticoagulation practice on patient survival. We conducted a consecutive retrospective analysis of postmortem COVID-19 (n = 64) and non-COVID-19 (n = 67) patients, as well as ante mortem COVID-19 (n = 170) patients admitted to the University Medical Center Hamburg-Eppendorf (Hamburg, Germany). Baseline patient characteristics, parameters related to the intensive care unit (ICU) stay, and the clinical and autoptic presence of VTE were evaluated and statistically compared between groups. The occurrence of VTE in critically ill COVID-19 patients is confirmed in both ante mortem (17%) and postmortem (38%) cohorts. Accordingly, comparing the postmortem prevalence of VTE between age- and sex-matched COVID-19 (43%) and non-COVID-19 (0%) cohorts, we found the statistically significant increased prevalence of VTE in critically ill COVID-19 cohorts (p = 0.001). A change in anticoagulation practice was associated with the statistically significant prolongation of survival time (HR: 2.55, [95% CI 1.41–4.61], p = 0.01) and a reduction in VTE occurrence (54% vs. 25%; p = 0.02). In summary, in the autopsy as well as clinical cohort of critically ill patients with COVID-19, we found that VTE was a frequent finding. A change in anticoagulation practice was associated with a statistically significantly prolonged survival time.

[1]  J. Halperin,et al.  Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.

[2]  M. Christner,et al.  SARS-CoV-2 Blood RNA Load Predicts Outcome in Critically Ill COVID-19 Patients , 2021, Open forum infectious diseases.

[3]  M. Aepfelbacher,et al.  Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases , 2021, Scientific Reports.

[4]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[5]  P. T. Ten Eyck,et al.  Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial , 2021, Journal of Thrombosis and Haemostasis.

[6]  H. Poor Pulmonary Thrombosis and Thromboembolism in COVID-19 , 2021, Chest.

[7]  Á. Avezum,et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[8]  G. Lip,et al.  Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID‐19 patients: A multicenter retrospective study , 2021, Journal of Thrombosis and Haemostasis.

[9]  J. Hochman,et al.  C-reactive protein and clinical outcomes in patients with COVID-19 , 2021, European heart journal.

[10]  U. Janssens,et al.  Recommendations on Inpatient Treatment of Patients with COVID-19. , 2021, Deutsches Arzteblatt international.

[11]  C. Heinz,et al.  Greater Fibrinolysis Resistance but No Greater Platelet Aggregation in Critically Ill COVID-19 Patients , 2021, Anesthesiology.

[12]  A. Tsakris,et al.  Association between upper respiratory tract viral load, comorbidities, disease severity and outcome of patients with SARS-CoV-2 infection , 2021, The Journal of infectious diseases.

[13]  Shuo Yan,et al.  High prevalence of occult thrombosis in cases of mild/moderate COVID-19 , 2020, International Journal of Infectious Diseases.

[14]  D. Wichmann Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[15]  H. Rohde,et al.  Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients , 2020, Blood Advances.

[16]  A. Belot,et al.  Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure , 2020, Annals of Intensive Care.

[17]  M. Aepfelbacher,et al.  Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19 , 2020, American journal of respiratory and critical care medicine.

[18]  B. Clary,et al.  Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis , 2020, EClinicalMedicine.

[19]  D. Jiménez,et al.  Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.

[20]  P. Enríquez,et al.  Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19 , 2020, Critical Care.

[21]  B. Bein,et al.  Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany , 2020, Australian Critical Care.

[22]  A. Pazin-Filho,et al.  Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) , 2020, Thrombosis Research.

[23]  F. Ozturk,et al.  Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis , 2020, The American Journal of Emergency Medicine.

[24]  T. Soumagne,et al.  Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients , 2020, European Respiratory Journal.

[25]  J. Dillner,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[26]  R. Busse,et al.  Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study , 2020, The Lancet Respiratory Medicine.

[27]  Simon A. Jones,et al.  Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. , 2020, JAMA.

[28]  Michael D Healy,et al.  SARS-CoV-2 viral load is associated with increased disease severity and mortality , 2020, Nature Communications.

[29]  M. Aepfelbacher,et al.  Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.

[30]  A. Lazo-Langner,et al.  Thrombosis risk associated with COVID-19 infection. A scoping review , 2020, Thrombosis Research.

[31]  J. Thachil,et al.  Coagulopathy of Coronavirus Disease 2019 , 2020, Critical care medicine.

[32]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[33]  M. Trauner,et al.  Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series , 2020, Annals of Internal Medicine.

[34]  M. Revel,et al.  Pulmonary embolism in patients with COVID-19 pneumonia , 2020, European Respiratory Journal.

[35]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[36]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[37]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[38]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[39]  Malik Peiris,et al.  Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.

[40]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[41]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[42]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) , 2019, European Respiratory Journal.

[43]  Diana Altshuler,et al.  Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient , 2018, Journal of intensive care medicine.

[44]  G. Ferretti,et al.  Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis , 2015, Critical Care.